Tonix Pharmaceuticals Holding (TNXP) Current Deferred Revenue (2012 - 2026)

Tonix Pharmaceuticals Holding's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 118.56% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 118.56% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 88.6% from the prior year.
• Current Deferred Revenue improved to $4.2 million in Q1 2026 per TNXP's latest filing, from $3.4 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $4.2 million in Q1 2026 and bottomed at $1.8 million in Q4 2024.
• The 5-year median for Current Deferred Revenue is $3.0 million (2023), against an average of $2.9 million.
• Across the five-year window, Current Deferred Revenue slumped 39.06% in 2024 and jumped 118.56% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $3.3 million in 2022, then retreated by 8.95% to $3.0 million in 2023, then slumped by 39.06% to $1.8 million in 2024, then soared by 88.6% to $3.4 million in 2025, then rose by 23.42% to $4.2 million in 2026.
• Per Business Quant, the three latest TNXP Current Deferred Revenue figures stand at $4.2 million (Q1 2026), $3.4 million (Q4 2025), and $2.7 million (Q3 2025).